Related Experiment Video
Updated: Aug 6, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
Can semaglutide influence tumor biomarkers? Insight from a clinical case
Alice Schianchi1, Fabio Mauri2, Christian Polli2
1Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Journal of Food and Drug Analysis
|July 22, 2026
Summary
This case study highlights a rare instance of elevated cancer biomarkers, CA 19-9 and CA-125, during Semaglutide treatment. These levels normalized, suggesting a potential link between Semaglutide and temporary biomarker fluctuations.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity.
- Elevated tumor biomarkers like CA 19-9 and CA-125 can indicate various conditions, including malignancy.
- The potential impact of Semaglutide on tumor biomarker levels is not well-established.